Unique enzymatic repertoire reveals the tumour

[1]  P. Poinot,et al.  Volatile Organic Compound (VOC)-Based Probe for Induced Volatolomics of Cancers. , 2019, Angewandte Chemie.

[2]  Molly M. Stevens,et al.  Renal clearable catalytic gold nanoclusters for in vivo disease monitoring , 2019, Nature Nanotechnology.

[3]  M. Grinstaff,et al.  Polymer–drug conjugate therapeutics: advances, insights and prospects , 2018, Nature Reviews Drug Discovery.

[4]  Nicolas Joubert,et al.  Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy. , 2017, European journal of medicinal chemistry.

[5]  Jarkko Rautio,et al.  Prodrugs in medicinal chemistry and enzyme prodrug therapies , 2017, Advanced drug delivery reviews.

[6]  A. Zelikin,et al.  Enzyme prodrug therapies and therapeutic enzymes. , 2017, Advanced drug delivery reviews.

[7]  S. Bhatia,et al.  Ultrasensitive tumour-penetrating nanosensors of protease activity , 2017, Nature Biomedical Engineering.

[8]  W. Wilson,et al.  Hypoxia-activated prodrugs: paths forward in the era of personalised medicine , 2016, British Journal of Cancer.

[9]  J. Scheuermann,et al.  A traceless vascular-targeting antibody-drug conjugate for cancer therapy. , 2012, Angewandte Chemie.

[10]  A. van Waarde,et al.  In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-β-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging β-Glucuronidase Activity in a Tumor/Inflammation Rodent Model , 2012, Molecular imaging.